The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
The researchers found that both coding and non-coding alterations drive the early development of multiple myeloma.
The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.
Researchers found rare mutations in USP45 and ARID1A by applying a shared genomic segment mapping approach to several large multiple myeloma-affected families.
In PLOS this week: approach to diagnose hemorrhagic fevers, recessive disease mutations in mixed-breed dogs, and more.
Mutations within BCL7A, BRWD3, and AUTS2 were more common among African Americans, while TP53 and IRF4 mutations were more frequent among Caucasians.
The trial will assess a novel treatment combination in genetically defined high-risk myeloma patients.
The Multiple Myeloma Research Foundation launched the MMRF Answer Fund to engage researchers, clinicians, and patients in the search for better treatments.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.